Keyphrases
AIDS Patients
8%
AIDS/HIV
35%
Amino
5%
Antiretroviral Naïve
6%
Antiretroviral Therapy
23%
Antiviral Activity
7%
Bali
11%
Bali Indonesia
8%
Buleleng
5%
COVID-19
18%
CRF01_AE
31%
Drug Combination
5%
Drug Resistance
8%
Drug Resistance mutations
26%
Drug-naïve Individuals
5%
Drug-treated
8%
East Java
6%
Env Gene
5%
Genotypic Characterization
11%
Helicobacter Pylori (H. pylori)
15%
Helicobacter Pylori Infection
8%
Hepatitis B Virus
6%
High Prevalence
6%
HIV Drug Resistance
9%
HIV Patients
19%
Hospitalized Patients
5%
Human Immunodeficiency Virus Drug Resistance
6%
Human Immunodeficiency Virus Infection
6%
Human Immunodeficiency Virus Type 1 (HIV-1)
68%
Human Immunodeficiency Virus/acquired Immunodeficiency Syndrome
7%
Immunoglobulin Y
8%
In Vitro Study
8%
Indonesia
100%
Indonesian
5%
Infected Individual
13%
Jakarta
5%
Major mutations
5%
Molecular Epidemiology
6%
Nave
7%
P24 Antigen
5%
Peripheral Blood Mononuclear Cells
7%
Reverse Transcriptase
6%
Reverse Transcriptase Gene
5%
Stakeholder Collaboration
5%
Surabaya
44%
Transmitted Drug Resistance
9%
Transmitted Drug Resistance mutations
5%
University Hospital
8%
Viral
8%
Virus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acquired Immune Deficiency Syndrome
6%
Anti-Human Immunodeficiency Virus
5%
Antibiotic Agent
5%
Antibiotics
6%
Antiviral Activity
7%
Antivirus Agent
9%
Azithromycin
5%
Combination Drug
5%
Disease
9%
Drug Resistance
32%
Helicobacter Pylori
11%
HIV
55%
Human Herpesvirus 8
5%
Human Immunodeficiency Virus 1
27%
Human Immunodeficiency Virus Infection
5%
Hydroxychloroquine
5%
Immunoglobulin Y
5%
Infection
16%
Infection Rate
5%
Inflammation
5%
Lopinavir Plus Ritonavir
5%
Opportunistic Infection
5%
Prevalence
19%
Proteinase
6%
RNA Directed DNA Polymerase
7%
RNA Directed DNA Polymerase Inhibitor
5%
SARS Coronavirus
8%
Medicine and Dentistry
Acquired Immune Deficiency Syndrome
5%
Antiretroviral Therapy
10%
COVID-19
12%
Disease
5%
Drug Resistance
17%
Helicobacter Pylori
8%
HIV Drug Resistance
6%
HIV/AIDS
5%
Human Herpesvirus 8
5%
Human Immunodeficiency Virus
24%
Human Immunodeficiency Virus 1
24%
Human Immunodeficiency Virus Infection
5%
Infection
12%
Molecular Epidemiology
5%
Prevalence
17%
Pylorus
8%
Resistance Mutation
7%